ストックスクリーナーアプリを入手
106.98
2.58%
-2.83
プレマーケット:
107.69
0.71
+0.66%
前日終値:
$109.81
開ける：
$108.43
24時間の取引高:
2.33M
Relative Volume:
1.62
時価総額：
$211.30B
収益：
$51.72B
当期純損益:
$11.94B
株価収益率:
18.19
EPS:
5.88
ネットキャッシュフロー:
$13.81B
1週間 パフォーマンス:
+2.13%
1か月 パフォーマンス:
+9.50%
6か月 パフォーマンス:
-2.80%
1年 パフォーマンス:
+3.12%
1日の値動き範囲:
$106.71
$108.73
1週間の範囲:
$104.07
$110.08
52週間の値動き範囲:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
106.98 | 211.30B | 51.72B | 11.94B | 13.81B | 5.88 |
|
LLY
Lilly Eli Co
|
870.37 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.17 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.51 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.97 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.05 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
Aplastic Anemia Global Clinical Trials Review 2024 | Now Available - GlobeNewswire Inc.
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart
Novartis at ASH - Novartis
Novartis Financial Results – Q1 2023 - Novartis
Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
J.P. Morgan Healthcare Conference 2024 - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Building belonging - Novartis
Novartis in Society Integrated Report 2024 - Novartis
Novartis to Report Q4 Earnings: What's in the Offing? - Yahoo Finance
AI Pharma: 2 Paths to AI-Powered Drug Investment - sharewise
Inari Medical Inc (NASDAQ: NARI): Getting A Free Pass? - Stocks Register
Metrics That Matter About Deutsche Bank AG (NYSE: DB) - Stocks Register
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Japan Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Canada Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead
Communiqué de presse - GlobeNewswire Inc.
Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha
Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.
5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart
5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar
Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
1.81%
大文字化:
|
ボリューム (24 時間):